Published by Josh White on 14th November 2024
(Sharecast News) - GSK reported positive results from its phase three 'DREAMM-7' trial on Thursday, highlighting a significant overall survival benefit for 'Blenrep', or belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.
URL: http://www.digitallook.com/dl/news/story/34690700/...